Lipid- and sugar-modified endomorphins: Novel targets for the treatment of neuropathic pain

Endomorphins are endogenous opioid peptides that cause potent antinociception in rodent models of acute and neuropathic pain with less undesirable side effects than opioid alkaloids. However, endomorphins are poorly suited to clinical applications because of low membrane permeability and a susceptib...

Full description

Saved in:
Bibliographic Details
Main Authors: Pegah eVaramini (Author), Istvan eToth (Author)
Format: Book
Published: Frontiers Media S.A., 2013-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_37a3e3f297b846e2919befd34a8d5b17
042 |a dc 
100 1 0 |a Pegah eVaramini  |e author 
700 1 0 |a Istvan eToth  |e author 
700 1 0 |a Istvan eToth  |e author 
245 0 0 |a Lipid- and sugar-modified endomorphins: Novel targets for the treatment of neuropathic pain 
260 |b Frontiers Media S.A.,   |c 2013-12-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2013.00155 
520 |a Endomorphins are endogenous opioid peptides that cause potent antinociception in rodent models of acute and neuropathic pain with less undesirable side effects than opioid alkaloids. However, endomorphins are poorly suited to clinical applications because of low membrane permeability and a susceptibility to enzymatic degradation. Glycosylation and lipidation have proven to be two of the most robust approaches for the generation of new therapeutic endomorphin derivatives. Conjugation with lipoamino acids (LAA) confers an amphipathic character to the peptide, which improved interaction between the peptide and the lipid bilayer of the cell membranes, increasing permeability. Glycosylation can also improve peptide stability and blood brain barrier (BBB) transport. It is believed that an endocytotic mechanism (transcytosis) is responsible for the systemic delivery of water-soluble glycopeptides. This review discusses the application of glycosylation and lipidation strategies to improve the drug-like properties of endomorphins. Pharmacologically active endomorphin analogues with less adverse effects are also discussed. 
546 |a EN 
690 |a Glycosylation 
690 |a neuropathic pain 
690 |a blood brain barrier 
690 |a lipopeptide 
690 |a Endomorphin 
690 |a Peptide delivery 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 4 (2013) 
787 0 |n http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00155/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/37a3e3f297b846e2919befd34a8d5b17  |z Connect to this object online.